



UvA-DARE (Digital Academic Repository)

Dysphagia, trismus and speech impairment following radiation-based treatment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation

Karsten, R.T.; Chargi, N.; van der Molen, L.; van Son, R.J.J.H.; de Bree, R.; Al-Mamgani, A.; de Boer, J.P.; Hilgers, F.J.M.; van den Brekel, M.W.M.; Smeele, L.E.; Stuijver, M.M.

DOI

[10.1007/s00405-021-06870-x](https://doi.org/10.1007/s00405-021-06870-x)

Publication date

2022

Document Version

Final published version

Published in

European Archives of Oto-Rhino-Laryngology

License

Article 25fa Dutch Copyright Act

[Link to publication](#)

Citation for published version (APA):

Karsten, R. T., Chargi, N., van der Molen, L., van Son, R. J. J. H., de Bree, R., Al-Mamgani, A., de Boer, J. P., Hilgers, F. J. M., van den Brekel, M. W. M., Smeele, L. E., & Stuijver, M. M. (2022). Dysphagia, trismus and speech impairment following radiation-based treatment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation. *European Archives of Oto-Rhino-Laryngology*, 279(2), 1003–1027. <https://doi.org/10.1007/s00405-021-06870-x>

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.



Dysphagia, trismus and speech impairment following radiation-based treatment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation

Rebecca T. Karsten¹ · Najiba Charki² · Lisette van der Molen^{1,3} · Rob J. J. H. van Son^{1,3} · Remco de Bree² · Abraham Al-Mamgani⁴ · Jan P. de Boer⁵ · Frans J. M. Hilgers^{1,3} · Michiel W. M. van den Brekel^{1,3} · Ludi E. Smeele^{1,6} · Martijn M. Stuiver¹

Received: 26 January 2021 / Accepted: 4 May 2021 / Published online: 27 May 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract

Objective The objective was to assess swallowing, mouth opening and speech function during the first year after radiation-based treatment (RT(+)) after introduction of a dedicated preventive rehabilitation program for stage III–IV oropharyngeal carcinoma (OPC).

Methods Swallowing, mouth opening and speech function were collected before and at six- and twelve-month follow-up after RT(+) for OPC as part of ongoing prospective assessments by speech-language pathologists.

Results Objective and patient-perceived function deteriorated until 6 months and improved until 12 months after treatment, but did not return to baseline levels with 25%, 20% and 58% of the patients with objective dysphagia, trismus and speech problems, respectively. Feeding tube dependency and pneumonia prevalence was low.

Conclusion Despite successful implementation, a substantial proportion of patients still experience functional limitations after RT(+) for OPC, suggesting room for improvement of the current rehabilitation program. Pretreatment sarcopenia seems associated with worse functional outcomes and might be a relevant new target for rehabilitation strategies.

Keywords Oropharyngeal carcinoma · Chemoradiotherapy · Radiotherapy · Dysphagia · Trismus · Speech · Sarcopenia

Introduction

The incidence of oropharyngeal cancer (OPC) has risen over the past decades, partially due to the rising incidence of human papilloma virus (HPV) associated cases [1]. In early stage OPC, surgery as well as radiotherapy (RT) are curative treatment options. In more advanced stages, especially when the disease is technically and functionally irresectable [2], organ preserving concurrent radiotherapy and systemic therapy (RT(+)) has become the common treatment modality.

Despite advancement in treatment, e.g. Intensity Modulated RT (IMRT) and Volumetric Modulated Arc Therapy (VMAT), and rehabilitation, e.g. the addition of prophylactic swallowing exercises to ameliorate functional sequelae related to the tumor and its treatment, negative side effects still do occur. Multiple studies have shown that RT(+) for OPC, although organ preserving, is accompanied with serious functional impairment and a decreased quality of life in the short- and long-term [3–6]. Apart from xerostomia, swallowing impairment (dysphagia), is the most important side effect,

✉ Michiel W. M. van den Brekel
m.vd.brekel@nki.nl

¹ Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

² Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands

³ Amsterdam Center for Language and Communication/ACLC-Institute of Phonetic Sciences, University of Amsterdam, Amsterdam, The Netherlands

⁴ Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

⁵ Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

⁶ Department of Oral and Maxillofacial Surgery, Academic Medical Center, Amsterdam, The Netherlands

which can worsen over time or even develop years after treatment [4, 7–10]. Impaired mouth opening (trismus), also commonly occurs after radiation-based treatment for OPC. Incidence rates of trismus vary across studies including patients with all head and neck cancer sites treated with surgery and/or RT(+), but oropharyngeal localization of the tumor consistently seems a significant risk factor [11–16]. Besides, RT(+) of the oropharynx also may affect articulation and speech [17]. Finally, a potential increased risk of carotid stenosis and cerebrovascular accidents has also been documented after RT(+) [18]. These negative side effects and the prolonged survival achieved with the improved treatment technologies over the last decades demand an increased awareness of functionality and quality of life after OPC treatment.

Most functional results at one-year post-treatment stay stable up until 5 years posttreatment, which makes functional status at 1 year posttreatment predictive of the 4 year thereafter [19]. Thorough knowledge on the course of functional limitations during the first year after RT(+) for OPC will thus aid in adequate pretreatment patient counseling, and the development and optimization of targeted and patient specific (preventive) rehabilitation protocols. Moreover, identification of risk factors might aid in the development of individualized rehabilitation programs. For example, the correlation of HPV status with functional outcome has never been studied, but might be a factor. Also, pretreatment sarcopenia, i.e. low skeletal muscle mass, is associated with unfavorable outcomes after treatment for head and neck cancer, including decreased survival and increased long-term feeding tube dependency, and might also be related to other post-treatment functional impairments [20, 21].

The objective of this study was to present OPC patients' objective and subjective swallowing function, mouth opening and speech data before and at 6 and 12 months after RT(+) (IMRT) after introduction of a dedicated preventive rehabilitation program, with special attention for the possible role of HPV and pretreatment sarcopenia. These data are relevant for the optimization of current rehabilitation protocols.

Methods

Ethical considerations

This study was approved by the Institutional Review Board of the Netherlands Cancer Institute—Antoni van Leeuwenhoek (NKI-AVL) (IRBd19044).

Patient selection

All patients diagnosed with head and neck cancer in the NKI-AVL, a tertiary cancer center, are followed up in

ongoing prospective assessments by speech-language pathologists, who intensively monitor functional limitations before, during and after treatment and start (additional) targeted rehabilitation.

For this analysis, Dutch speaking patients were included who were curatively treated with primary RT or RT + (RT with cisplatin or cetuximab) for a stage III-IV squamous cell carcinoma of the oropharynx between January 2013 and September 2018. Patients were excluded in case of distant metastases, a synchronous primary tumor elsewhere, prior treatment of the head and neck area (except neck dissection or skin lesions), missing pre-treatment assessment data or if only pretreatment assessment data were available. Patients were excluded from follow-up of this study when additional oncological treatment was given due to residual or recurrent disease.

Radiotherapy based treatment

According to protocol, the treatment consisted of radiotherapy given with 6 MV photons up to 70 Gy in 35 fractions in 6 weeks in case of RT alone and 7 weeks in case of RT + using sequential or simultaneous integrated boost (SIB) according to the IMRT technique (either step and shoot or VMAT). Patients receiving sequential integrated boost were given an elective dosage of 46 Gy (23 fractions of 2 Gy) with a total dosage of 70 Gy (35 fractions of 2 Gy). Patients receiving simultaneous integrated boost were given an elective dosage of 54.25 Gy (35 fractions of 1.55 Gy) with a total dosage of 70 Gy (35 fractions of 2 Gy).

Concurrent systemic treatment (which was indicated in case of stage N2b or higher or extranodal spread) consisted of cisplatin or cetuximab. Cisplatin was administered intravenously either in high-dose (100 mg/m² at day 1, 22 and 43 of radiotherapy), intermediate-dose (40 mg/m² every week), or low-dose (6 mg/m² daily during the first 5 weeks of radiotherapy). Cetuximab was given when patients were unfit for cisplatin. One week before the start of RT, a loading dose of 400 mg/m² was administered, followed by 250 mg/m² weekly during 7 weeks.

Preventive rehabilitation protocol

Since studies have suggested benefit of preventive rehabilitation during RT(+), in April 2008 a preventive rehabilitation trial was conducted in the NKI-AVL, comparing preventive rehabilitation with and without the TheraBite Jaw Motion Rehabilitation System™ [22]. Despite the fact that in a subsequent study the cost-effectiveness of the protocol with the TheraBite was shown [23], reimbursement of this rehabilitation tool unfortunately was not achieved due to small differences in effectiveness compared to standard rehabilitation without the TheraBite. In 2011 reimbursement was achieved

for a preventive rehabilitation program including standard swallowing rehabilitation only, which was clinically implemented during 2012, with 2013 as the first full year of its implementation [24]. All patients in the present study were instructed to perform preventive swallowing and mouth opening exercises daily from the start of treatment up until at least 3 months afterwards. In short, this included performing the following set of exercises three times a day: range-of-motion (stretch) exercises and three muscle strengthening exercises (i.e., effortful swallow, Masako maneuver, and super-supraglottic swallow). No data on adherence to the protocol was collected.

Data collection

Baseline characteristics collected included gender, age at start treatment, comorbidity according to the Adult Comorbidity Evaluation-27 (ACE-27) index, body mass index (BMI), tumor site, T and N classification (AJCC 7th edition, used at time of diagnosis), AJCC stage, HPV status and treatment modality. HPV status was determined using immunohistochemistry for p16 and p53. In case immunohistochemistry did not provide a definite result, polymerase chain reaction was used. Skeletal muscle mass was assessed at baseline. This was performed by measuring the total cross-sectional muscle areas (CSMA) of the bilateral paravertebral and sternocleidomastoid muscles on a single CT slice at the level of C3 using the software tool SliceOmatic, as described previously [20, 25, 26]. Routine pretreatment CT- of PET/CT scans were used for this purpose. The transformation formula of Swartz et al. was used to estimate CSMA at L3 level [25]. The lumbar skeletal muscle mass (LSMI) was calculated by normalizing the CSMA for height, from here called the skeletal mass index (SMI). Lower values of the lumbar SMM indicate lower skeletal muscle mass with values below 43.2 cm²/m² indicating sarcopenia [26].

Furthermore, swallowing, mouth opening and speech outcomes were collected from the speech-language pathologists' records. For each domain an observer- as well as patient-rated outcome measure was collected before (*t*0) and 6 (*t*1) and 12 months (*t*2) post RT(+) as described below.

Swallowing outcomes

The primary observer-rated swallowing outcome was the functional oral intake scale (FOIS) which is a validated seven-point ordinal scale with lower scores indicating more intake problems [27]. As primary patient-rated swallowing outcome, the SWAL-QOL was used. This is a validated 44-item questionnaire on dysphagia and its influence on daily life. It includes ten domains: burden*, food selection*, eating duration*, eating desire*, fear*, sleep, fatigue, communication, mental health*, social functioning*, and

symptom frequency. The total SWAL-QOL score is calculated from the subscales marked with an asterisk. All scores range from 0 to 100 with higher scores indicating more dysphagia-related problems [28, 29].

Secondary swallowing outcomes included feeding tube dependence and pneumonia during the past 6 months.

Mouth opening outcomes

The primary observer-rated trismus outcome was the mouth opening (maximum central inter-incisal opening) measured in millimeters using the TheraBite[®] Jaw Range of Motion Scale (Atos Medical AB, Hörby, Sweden). When a patient was missing the central incisors, 19 mm was subtracted from the score [30]. The patient-rated outcome was collected by means of a single item question on whether the patient experienced the mouth opening as limited.

Voice and speech outcomes

To assess observer-rated voice and speech outcomes, audio recordings were made of patients performing a set of speech tasks which included respectively reading aloud a 149 word long Dutch reading text called ‘‘Tachtig dappere fietsers’’ (Eighty brave cyclists), a word list, and sustained vowels (/a/,/i/,and/u/). All recordings were analyzed using the PRAAT program [31].

The primary observer-rated speech outcome was the vowel space area, a measure of articulation, for which the read text was used, or the word list if the text was not available. It was calculated as a percentage of the maximum total area of the vowel triangle [32]. In this study, values below 80% were used to indicate abnormal articulation.

The primary patient-rated speech outcome was the Speech Handicap Index (SHI). This is a thirty-item speech-related quality of life questionnaire on which a patient indicates the frequency of problems experienced on a five-point scale: never (=0), almost never (=1), sometimes (=2), almost always (=3), and always (=4). The score can range from 0 to 120 with higher scores indicating more speech-related problems. A psychosocial and a speech function subscale can be calculated from these thirty questions. The SHI also includes one global question indicating the overall speech quality (excellent (=0), good (=30), average (=70), and bad (=100)) [33, 34].

Secondary speech outcomes were the articulation rate in syllables per second, which was measured from the reading text using a script in PRAAT [35]. The voice outcome measure was the acoustic voice quality index (AVQI), which was determined using a combination of 3 s of the sustained /a/ and 4 s of the read text [36, 37]. If no 3 s of /a/ was available, a combination of the sustained vowel records was used. If the read text was not present, 4 s of the word list was used.

This outcome ranges from 1 to 10, with 1 being most equal to normal and 10 least equal to normal. A value of the AVQI less than 2.95 was considered a good voice quality [38].

Statistical analysis

Analyses were performed using IBM® SPSS® Statistics 25.0. Baseline characteristics were presented using descriptive statistics. To test whether patient and tumor characteristics of the patients at t_0 , t_1 and t_2 were different, the Kruskal–Wallis test was used for continuous data and the linear-by-linear approximation of the Pearson's Chi-square test (exact two-sided p value) for dichotomous and ordinal data. To test differences in baseline characteristics of included patients and patients who were excluded because they either had only data at t_0 available or did not have data at t_0 available, the Mann–Whitney U test for continuous data was used, the linear-by-linear approximation of the Pearson's Chi-square test (exact two-sided significance) for ordinal data and the Fisher's exact test for dichotomous data. Proportions and percentages were used to describe dichotomous outcomes and the median and range were used to describe all continuous outcomes. Differences between three timepoints were statistically analyzed by means of paired tests (i.e. Friedman test for continuous or ordinal data and a Cochran's Q for dichotomous data) as well as the differences between two timepoints (i.e. Wilcoxon signed rank test for continuous or ordinal data and the McNemar test for dichotomous data). Univariable logistic regression analysis was used to explore factors related to dysphagia (FOIS < 7), trismus (mouth opening < 36 mm) and abnormal articulation (vowel space area > 80%) at t_2 . Differences in outcomes between HPV positive and negative patients and patients with and without pretreatment sarcopenia were assessed. Differences in baseline characteristics were assessed by means of the Mann–Whitney U test for continuous data, the linear-by-linear approximation of the Pearson's Chi-square test (exact two-sided p value) for ordinal data and the Fisher's exact test for dichotomous data. Associations were adjusted for confounders and mediators, chosen dependent on the outcome of interest (T and N classification, treatment and modified diet at t_0 for differences in HPV classification; AJCC stage and modified diet at t_0 for sarcopenia) by means of multivariable logistic or linear regression analyses. Overall, findings were considered statistically significant when the p value was less than 0.05. For all post-hoc pairwise comparisons, we considered a p value less than 0.01 statistically significant to account for multiple testing.

Results

Between January 2013 and September 2018, 248 patients with stage III–IV oropharyngeal squamous cell carcinomas were curatively treated with RT(+) at our institute of whom

106 patients were excluded from these analyses. Twenty-two patients were excluded because of previous treatment in the head and neck area ($n = 7$), a second primary tumor elsewhere ($n = 14$) or not speaking Dutch ($n = 1$). Eighty-four patients were eligible, but were excluded because of unavailable outcome data, due to several reasons: patient canceled pretreatment appointment ($n = 4$), appointment was not made ($n = 40$) or appointment was made, but assessments were not obtained ($n = 40$). Baseline characteristics of these 84 patients are shown in Table 1 and showed no significant differences with the included patients. Percentages of patients not included in the data assessment per accrual year are presented in Fig. 1. This figure also shows that the accrual increased from 19% in 2013 to 85% in 2018, with a slight decrease to 79% in 2019. Prevalence of functional impairment was comparable between patients included in 2013–2014 and 2017–2018 (appendix see Table 5).

In total, pretreatment data was assessed of 142 patients curatively treated with primary RT(+) for OPC. A further 34 patients had to be excluded due to missing follow-up data (11 patients withdrew, 3 patients did not receive a follow-up appointment, 15 had recurrent/residual disease, 1 developed second primary in the lung within the first 6 months post treatment, and 5 died (due to aspiration pneumonia, abdominal sepsis, sudden death, peritonitis or bleeding during alcohol abuse).

This left 108 patients for inclusion in the current analysis. Ninety-nine patients (92%) were present at t_1 and 71 patients (66%) at t_2 with 62 patients (57%) present at all three assessments. In appendix see Fig. 2 the reasons for loss to follow-up are presented. Median follow-up time at t_1 was 6 months (range 2–9 months) and 12 months (range 8–18 months) at t_2 .

Baseline characteristics

Baseline characteristics are presented in Table 1. Of the 108 included patients, 73 (67%) were male, 53 patients (49%) had an ACE-27 score > 0 indicating comorbidity, 49 patients (45%) had sarcopenia, 35 patients (32%) had a tumor located in the base of tongue, 80 (74%) had stage IV disease and 70 (68%) were HPV positive. There were no significant differences regarding these characteristics between the patients present at the different assessments. Patients who were excluded because only t_0 data was available ($n = 34$), had higher tumor stages, and had more often a modified diet pretreatment (FOIS < 7) and trismus. Patients who were eligible but not included in the study ($n = 84$) were comparable to the included patients with regard to patient, tumor and treatment characteristics. However, baseline BMI, SMM, presence of sarcopenia, FOIS and mouth opening were not available for these patients.

Table 1 Baseline characteristics of patients at *t*0, *t*1 and *t*2

	<i>t</i> 0 <i>n</i> = 108	<i>t</i> 1 <i>n</i> = 99	<i>t</i> 2 <i>n</i> = 71	<i>P</i> value <i>t</i> 0, <i>t</i> 1, <i>t</i> 2	Only <i>t</i> 0 available <i>n</i> = 34	<i>P</i> value <i>t</i> 0, only <i>t</i> 0	Not included because no <i>t</i> 0 available <i>n</i> = 84	<i>P</i> value <i>t</i> 0, no <i>t</i> 0
Gender								
Male	73 (68)	68 (69)	52 (73)	0.461 ^b	24 (71)	0.834 ^d	54 (64)	0.648 ^d
Female	35 (32)	31 (31)	19 (27)		10 (29)		30 (36)	
Age at baseline median (range)	63 (39–81)	63 (39–81)	60 (39–77)	0.499 ^a	65 (49–78)	0.316 ^c	62 (47–83)	0.530 ^c
ACE-27								
0	53 (49)	46 (47)	39 (55)	0.357 ^b	14 (41)	0.248 ^b	37 (44)	0.442 ^b
1	37 (34)	35 (35)	26 (37)		10 (29)		30 (36)	
2	14 (13)	14 (14)	3 (4)		9 (27)		13 (16)	
3	4 (4)	4 (4)	3 (4)		1 (3)		4 (5)	
BMI median (range)	25 (17–44)	25 (17–44)	26 (17–44)	0.791 ^a	24 (49–78)	0.127 ^d		
SMM median (range)	44 (22–64)	44 (22–64)	45 (22–64)	0.506 ^a				
Sarcopenia								
No	59 (55)	53 (54)	44 (62)	0.402 ^b				
Yes	49 (45)	46 (47)	27 (38)					
Oropharyngeal tumor site								
Base of tongue	35 (32)	33 (33)	25 (35)	0.819 ^b	13 (38)	0.888 ^b	31 (37)	0.685 ^b
Tonsil	57 (53)	54 (55)	35 (49)		13 (38)		33 (39)	
Other	16 (15)	12 (12)	11 (16)		8 (24)		20 (24)	
T classification								
T1	27 (25)	23 (23)	19 (27)	0.832 ^b	4 (12)	0.006 ^b	22 (26)	0.791 ^b
T2	30 (28)	30 (30)	19 (27)		8 (24)		28 (33)	
T3	29 (27)	25 (25)	20 (28)		5 (15)		14 (17)	
T4	22 (20)	21 (21)	13 (18)		17 (50)		20 (24)	
N classification								
N0	12 (11)	11 (11)	8 (11)	0.794 ^b	3 (9)	0.589 ^b	6 (7)	0.205 ^b
N1	24 (22)	22 (22)	13 (18)		7 (21)		14 (17)	
N2	69 (64)	63 (64)	48 (68)		22 (65)		62 (74)	
N3	3 (3)	3 (3)	2 (3)		2 (6)		2 (2)	
AJCC stage								
III	28 (26)	25 (25)	18 (25)	0.931 ^b	4 (12)	0.102 ^d	17 (20)	0.394 ^d
IV	80 (74)	74 (75)	53 (75)		30 (88)		67 (80)	
HPV status								
Negative	33 (32)	31 (31)	18 (26)	0.454 ^b	14 (47)	0.192 ^d	29 (40)	0.267 ^d
Positive	70 (68)	64 (67)	51 (74)		16 (53)		43 (60)	
Unknown	5	4	2		4		12	
Treatment modality								
RT	39 (36)	36 (36)	26 (37)	0.973 ^b	9 (27)	0.384 ^b	33 (39)	0.481 ^b
RT unfit for RT+	3 (3)	3 (3)	2 (3)		2 (6)		6 (7)	
RT+ cetuximab	17 (16)	17 (17)	11 (16)		7 (21)		12 (14)	
RT+ cisplatin	49 (45)	43 (43)	32 (45)		16 (47)		33 (39)	
Modified diet at <i>t</i> 0 (FOIS < 7)								
No	89 (82)	81 (82)	66 (93)	0.090 ^b	23 (72)	0.212 ^d	NA	
Yes	19 (18)	18 (18)	5 (7)		9 (28)			
Unknown	0	0	0		2			
Trismus at <i>t</i> 0								
No	98 (94)	91 (96)	64 (94)	1.000 ^b	21 (66)	<0.001 ^d	NA	
Yes	6 (6)	4 (4)	4 (6)		11 (34)			
Unknown	4	4	3		2			

NB Not all percentages sum up exactly to 100% due to rounding

BMI body mass index, *HPV* human papilloma virus, *FOIS* functional oral intake scale, *other* soft palate, uvula, oropharyngeal wall, vallecula or pharyngeal arch, *RT* radiotherapy, *SMM* skeletal muscle mass, *t*0 pretreatment, *t*1 6 months after treatment, *t*2 12 months after treatment, *sarcopenia* SMM below 43.2 cm²/m²

^a*P* values shown for Kruskal–Wallis test

^bLinear-by-linear approximation of the Pearson's Chi-square test

^cMann Whitney *U* test

^dFisher's exact test




Fig. 1 Percentages of ‘missed’ patients per accrual year. ‘Missed’ patients are defined as patients who were eligible and willing to participate but data at t_0 was not collected

Of the 108 included patients, 42 were treated with RT only (39 by tumor indication and 3 because they were unfit for systemic therapy), and 66 with RT + (49 with cisplatin and 17 with cetuximab). Patients treated with RT + more often had pretreatment sarcopenia, obviously had higher tumor stages, and more often had HPV negative tumors. All baseline characteristics categorized by treatment modality are presented in appendix see Table 6.

Swallowing outcomes

Swallowing outcomes are presented in Fig. 3a and Table 2. On average, the prevalence of swallowing problems was higher at t_1 compared to t_0 , and this decreased afterwards although not returning to baseline. This was true for the percentage of patients who needed a modified diet (FOIS < 7), the median total SWAL-QOL score, as well as for most subscales of the SWAL-QOL. Respectively 2 (2%), 6 (6%) and 0 patients (0%) were feeding tube dependent at t_0 , t_1 and t_2 . At t_0 , 4 patients (4%) had suffered from a pneumonia in the 6 months prior to the assessment. At t_1 , this concerned 3 patients (3%), of whom one also had a pneumonia before t_0 . At t_2 , this concerned 3 patients (4%), none of whom had suffered from a pneumonia before t_0 or t_1 .

Swallowing outcomes stratified by treatment modality, resulting in relatively small numbers per group, are presented in appendix see Table 7.

Trismus outcomes

Trismus outcomes are presented in Fig. 3b and Table 3. The prevalence of trismus was highest at t_1 compared to t_0 as well as t_2 . The prevalence at t_2 remained higher than at t_0 . Perceived trismus followed the same trend, however, not all patients with objective trismus (mouth opening < 36 mm) perceived their mouth opening as impaired (Fig. 3b).

Trismus outcomes stratified by treatment modality, resulting in relatively small numbers per group, are presented in appendix see Table 8.

Speech and voice outcomes

Speech and voice outcomes are presented in Fig. 3c and Table 4. The median vowel space area at t_1 was lower than at t_0 . At t_2 , the median vowel space area was lower than at t_1 , suggesting worsening articulation. Articulation rate and voice quality (AVQI) did not change over time. More patients had speech-related problems in daily life, as assessed with the SHI, at t_1 compared to t_0 .

Speech and voice outcomes stratified by treatment modality, resulting in relatively small numbers per group, are presented in appendix see Table 9.

Factors associated with functional limitations

Appendix see Table 10 shows the baseline characteristics stratified by patients who did or did not have a modified diet (FOIS < 7) at t_2 . A modified diet at t_2 was univariably associated with pretreatment lower BMI, lower SMI, sarcopenia, and a T4 tumor.

Appendix see Table 11 shows the baseline characteristics stratified by patients who had trismus (mouth opening < 36 mm) at t_2 . Trismus at t_2 was univariably associated with tumor site other than base of tongue and tonsil (i.e. soft palate, uvula, pharyngeal wall, vallecula, and pharyngeal arches).


Appendix see Table 12 shows the baseline characteristics stratified by patients who had a vowel space below 80%, indicating abnormal articulation, at t_2 . A vowel space below 80% at t_2 was univariably associated with a pretreatment vowel space area below 80% only.

HPV status

Appendix see Table 13 shows the baseline characteristics stratified by HPV status. Compared to patients with an HPV negative tumor, patients with an HPV associated tumor had a higher BMI, higher SMI, lower T classifications, higher N classification, were more often treated with RT only, and had less often a modified diet at baseline.

Functional outcomes at t_0 , t_1 and t_2 stratified by HPV status are presented in appendix see Table 14. At t_1 and t_2 , patients with an HPV negative tumor more often had a modified diet compared to patients with an HPV positive tumor. Also, SWAL-QOL scores were higher in the HPV negative group at both t_1 and t_2 . The prevalence of trismus was comparable between the HPV negative and positive patients at t_1 . At t_2 , however, trismus was less prevalent in HPV negative patients compared to HPV positive patients. Patients with an HPV negative tumor also had slightly worse speech and voice outcomes, especially at t_1 . After adjusting for T and N classification, treatment and pretreatment modified diet, none of the differences were statistically significant,

Fig. 2 Follow-up flowchart



except at *t2*, patients with an HPV positive tumor had a smaller mouth opening.

Sarcopenia

Appendix see Table 15 shows the baseline characteristics stratified by pretreatment sarcopenia. Patients with pretreatment sarcopenia were more often female, had a lower BMI, higher T classifications, higher disease stages, more often

an HPV negative tumor, and more often had a modified diet at baseline compared to patients without pretreatment sarcopenia.

All outcomes stratified by pretreatment sarcopenia are presented in appendix see Table 16. Pretreatment sarcopenia was associated with more modified diet at all time-points. Also, at *t0* and *t1*, SWAL-QOL scores were higher in patients with sarcopenia, indicating more swallowing related problems. At *t2*, SWAL-QOL scores were comparable.




Fig. 3 Percentage of patients with subjective and objective functional limitations at t_0 , t_1 and t_2 . Numbers of patients with available data per variable in legend. *SHI* speech handicap index, *VSA* vowel space area

Trismus outcomes were comparable between patients with and without sarcopenia at t_0 , t_1 and t_2 . Prevalence of objective speech problems (vowel space area below 80%) was comparable at t_0 and t_1 , but higher in patients with sarcopenia at t_2 . Patient reported speech problems, however, were more prevalent in patients with sarcopenia. After adjusting for AJCC stage and pretreatment modified diet, only modified diet and the total SWAL-QOL score at t_1 were significantly higher in patients with pretreatment sarcopenia.

Discussion

The objective of this study was to assess objective and subjective swallowing function, mouth opening and speech over a one-year period in a large cohort after RT(+) for advanced stage OPC treatment after introduction of a dedicated preventive rehabilitation program, also focusing on the role of HPV status and pretreatment sarcopenia. These results are relevant for the optimization of current rehabilitation protocols. Patients were treated with IMRT with or without systemic therapy and a concurrent preventive rehabilitation program. Data collection was part of a systematic, intensive routine monitoring program at our institute to evaluate outcomes after the implementation of this dedicated preventive

rehabilitation program. Accrual to this study increased from 19% in 2013 to 85% in 2018, with a slight decrease to 79% in 2019, indicating increased awareness regarding the rehabilitation program and its evaluation amongst our medical staff. The study showed that the normalcy of oral intake and SWAL-QOL scores first deteriorated up to 6 months, and subsequently improved up until 12 months after treatment, but did not return to baseline levels. Rate of feeding tube dependency in this cohort was low, with none of the patients being feeding tube dependent at 1 year after treatment. Also, very few patients experienced pneumonia during the one-year follow-up. Trismus and speech problems showed the same trend as swallowing function, with increased prevalence of problems at six-month follow-up, and lower—but still above baseline—prevalence rates at one-year post-treatment. Patients treated with cisplatin-based RT +, HPV negative tumors, and patients with pretreatment sarcopenia were more likely to have functional limitations. Patients treated with RT + had worse swallowing, trismus and speech and voice outcomes, compared to those treated with RT alone.

Most of the above summarized outcomes were in line with expectations and are comparable to those of other studies concluding that a substantial proportion of the patients have functional impairment after treatment. Although it is hard to compare the present results to other studies given the

Table 2 Swallowing outcomes at *t*0, *t*1 and *t*2

	Total			<i>P</i> value <i>t</i> 0, <i>t</i> 1, <i>t</i> 2	<i>P</i> value <i>t</i> 0 to <i>t</i> 1	<i>P</i> value <i>t</i> 1 to <i>t</i> 2	<i>P</i> value <i>t</i> 0 to <i>t</i> 2
	<i>t</i> 0 <i>n</i> = 108	<i>t</i> 1 <i>n</i> = 99	<i>t</i> 2 <i>n</i> = 71				
Observer-rated outcome							
FOIS							
7	89 (82)	65 (66)	53 (75)	0.012 ^a	0.195 ^c	0.499 ^c	0.043 ^c ↑
6	8 (7)	24 (25)	14 (20)				
5	7 (7)	4 (4)	3 (4)				
4	2 (2)	1 (1)	1 (1)				
3	2 (2)	4 (4)	0 (0)				
2	0 (0)	0 (0)	0 (0)				
1	0 (0)	0 (0)	0 (0)				
Unknown	0	1	0				
Modified diet (FOIS < 7)							
No	89 (82)	65 (66)	53 (75)	0.005 ^b	0.012 ^d ↑	0.832 ^d	0.004 ^d ↑
Yes	19 (18)	33 (34)	18 (25)				
Unknown	0	1	0				
Patient-rated outcome							
SWAL-QOL (0–100) median (range)							
General burden	0 (0–88)	0 (0–100)	0 (0–50)	0.004 ^a	0.001 ^c ↑	0.620 ^c	0.010 ^c ↑
Food selection	0 (0–88)	25 (0–100)	0 (0–50)	<0.001 ^a	<0.001 ^c ↑	0.031 ^c ↓	0.001 ^c ↑
Eating duration	13 (0–88)	38 (0–100)	38 (0–100)	<0.001 ^a	<0.001 ^c ↑	0.431 ^c	<0.001 ^c ↑
Eating desire	8 (0–92)	17 (0–83)	8 (0–67)	0.003 ^a	0.001 ^c ↑	0.245 ^c	0.002 ^c ↑
Fear	0 (0–69)	0 (0–69)	0 (0–38)	0.066 ^a	0.002 ^c ↑	0.490 ^c	0.031 ^c ↑
Sleep	38 (0–75)	38 (0–75)	25 (0–88)	0.044 ^a	0.307 ^c	0.003 ^c ↓	0.372 ^c
Fatigue	25 (0–67)	29 (0–75)	17 (0–83)	0.001 ^a	0.001 ^c ↑	0.177 ^c	0.055 ^c
Communication	0 (0–75)	0 (0–75)	0 (0–63)	0.087 ^a	0.008 ^c ↑	0.780 ^c	0.065 ^c
Mental health	0 (0–75)	0 (0–100)	0 (0–45)	0.138 ^a	0.002 ^c ↑	0.391 ^c	0.182 ^c
Social functioning	0 (0–70)	0 (0–60)	0 (0–30)	0.215 ^a	0.002 ^c ↑	0.349 ^c	0.233 ^c
Symptoms	7 (0–79)	16 (0–52)	13 (0–41)	0.003 ^a	<0.001 ^c ↑	0.032 ^c	0.003 ^c ↑
Total score	5 (0–69)	14 (0–77)	9 (0–43)	<0.001 ^a	<0.001 ^c ↑	0.342 ^c	<0.001 ^c ↑
SWAL-QOL ≥ 14							
No	52 (67)	35 (52)	38 (72)	0.307 ^b	0.057 ^d	0.754 ^d	0.388 ^d
Yes	26 (33)	32 (48)	15 (28)				
Unknown	30	32	18				
Secondary outcomes							
Feeding tube							
No	106 (98)	93 (94)	71 (100)	0.018 ^b	0.289 ^d	0.125 ^d	1.000 ^d
Yes	2 (2)	6 (6)	0 (0)				
Pneumonia							
No	98 (96)	90 (97)	67 (96)	0.050 ^b	1.000 ^d	0.250 ^d	1.000 ^d
Yes	4 (4)	3 (3)	3 (4)				
Unknown	6	6	1				

NB Not all percentages sum up exactly to 100% due to rounding

FOIS functional oral intake scale, *NGT* nasogastric tube, *PRG* percutaneous radiological gastrostomy, *t*0 pretreatment, *t*1 6 months after treatment, *t*2 12 months after treatment

^a*P* values shown for Friedman test

^bCochran’s Q test

^cWilcoxon signed rank test

^dMcNemar test

↑ Indicating more problems

↓ Indicating less problems

Table 3 Trismus outcomes at *t*0, *t*1 and *t*2

	Total			<i>P</i> value	<i>P</i> value	<i>P</i> value	<i>P</i> value
	<i>t</i> 0 <i>n</i> = 108	<i>t</i> 1 <i>n</i> = 99	<i>t</i> 2 <i>n</i> = 71	<i>t</i> 0, <i>t</i> 1, <i>t</i> 2	<i>t</i> 0 to <i>t</i> 1	<i>t</i> 1 to <i>t</i> 2	<i>t</i> 0 to <i>t</i> 2
Observer-rated outcomes							
Mouth opening in mm median (range)	48 (18–65)	45 (16–63)	43 (10–64)	<0.001 ^a	<0.001 ^c ↑	0.497 ^c	<0.001 ^c ↑
Trismus							
No	98 (94)	68 (77)	55 (80)	0.006 ^b	<0.001 ^d ↑	1.000 ^d	0.039 ^d ↑
Yes	6 (6)	20 (23)	14 (20)				
Unknown	4	11	2				
Patient-rated outcomes							
Perceived trismus							
No	87 (97)	67 (82)	56 (89)	0.082 ^b	0.022 ^d ↑	0.065 ^d	0.453 ^d
Yes	3 (3)	15 (18)	7 (11)				
Unknown	18	17	8				

NB Not all percentages sum up exactly to 100% due to rounding

FOIS functional oral intake scale, *NGT* nasogastric tube, *PRG* percutaneous radiological gastrostomy, *t*0 pretreatment, *t*1 6 months after treatment, *t*2 12 months after treatment

^a*P* values shown for Friedman test

^bCochran's Q test

^cWilcoxon signed rank test

^dMcNemar test

↑Indicating more problems

↓Indicating less problems

heterogeneity of cohorts and outcome measures currently used, some comparisons can be made. Starmer et al. evaluated 71 patients with OPC treated with IMRT with or without systemic therapy and preventive swallowing rehabilitation around 5 months post-treatment [9]. Probably because 92% of the patients received RT+, prevalence of a modified diet according to FOIS scores was higher in that study (86% compared to 34% in our study). Hunter et al. evaluated the two-year period after RT+ without preventive swallowing rehabilitation for stage III-IV OPC in 72 patients [10]. At 6 and 12 months after treatment respectively, 6% and 2% had grade 2 dysphagia (modified diet) and 6% and 1% had grade 3 dysphagia (feeding tube dependence) according to the Common Toxicity Criteria Adverse Effects (CTCAE) scale. The significantly lower percentage of patients with a modified diet in that study may, in part, be because another outcome measure was used (CTCAE scale versus FOIS). Congruent with our finding, other studies also found that functional limitations worsened the first months after therapy and improved through 12 months after treatment with minimal improvement in the year thereafter [10, 39].

Only few studies have investigated trismus within the first year after radiation-based treatment and a preventive rehabilitation protocol for advanced stage OPC. Kraaijenga et al. found that 9 of 24 patients (27%) after RT+ for OPC

had trismus at a median follow-up of 13 weeks [16]. In our study this concerned 23% at six-month follow-up and 20% at twelve-month follow-up. Incidence rates of trismus in other studies including all head and neck cancer localizations treated with surgery and/or radiation vary, but oropharyngeal localization of the tumor consistently seems a risk factor [11–15, 40]. This is probably because treatment of the oropharynx causes fibrosis in the mastication musculature [16]. This hypothesis is also supported by our results showing that patients with tumor localizations within the oropharynx other than base of tongue have trismus more often.

Apparently, despite trismus preventing measures in our preventive rehabilitation program, trismus is still a prevalent problem in this cohort. Therefore, extra measures could be taken to prevent and treat trismus, for example, by selecting high risk patients for more intensive guidance, and emphasizing the need for trismus prevention stronger, prior to treatment. The consistent use of mouth opening exercises (e.g. with tongueblades or TheraBite®) in this patient group might have been advantageous [41]. The lack of reimbursement for TheraBite® in the Netherlands, preventing regular use of this medical device in our patient population, is noteworthy in this respect.

With respect to speech and voice outcomes, according to our results, observer-rated intelligibility was deteriorated

Table 4 Speech and voice outcomes at *t*0, *t*1 and *t*2

	Total			<i>P</i> value <i>t</i> 0, <i>t</i> 1, <i>t</i> 2	<i>P</i> value <i>t</i> 0 to <i>t</i> 1	<i>P</i> value <i>t</i> 1 to <i>t</i> 2	<i>P</i> value <i>t</i> 0 to <i>t</i> 2
	<i>t</i> 0 <i>n</i> = 108	<i>t</i> 1 <i>n</i> = 99	<i>t</i> 2 <i>n</i> = 71				
Observer-rated outcomes							
Vowel space area (%) median (range)	85 (51–129)	79 (49–107)	77 (51–112)	0.014 ^a	0.015 ^c ↑	0.137 ^c	0.002 ^c ↑
Vowel space area < 80%							
No	59 (63)	37 (49)	24 (42)	0.050 ^b	0.210 ^d	0.344 ^d	0.019 ^d ↑
Yes	35 (37)	39 (51)	33 (58)				
Unknown	14	23	14				
Patient-rated outcomes							
SHI median (range)							
Speech domain (0–56)	0 (0–42)	2 (0–32)	0 (0–31)	0.076 ^a	0.005 ^c ↑	0.045 ^c ↓	0.580 ^c
Psychosocial domain (0–56)	0 (0–39)	0 (0–34)	0 (0–15)	0.326 ^a	0.476 ^c	0.236 ^c	0.281 ^c
Total score (0–120)	0 (0–83)	3 (0–61)	0 (0–40)	0.190 ^a	0.001 ^c ↑	0.073 ^c	0.640 ^c
SHI ≥ 6							
No	65 (83)	39 (66)	36 (88)	0.074 ^b	0.006 ^d ↑	0.453 ^d	0.500 ^d
Yes	13 (17)	20 (34)	5 (12)				
Unknown	30	40	30				
Secondary outcomes							
Articulation rate (syllables/s) median (range)	2.3 (0.2–7.7)	2.6 (0.6–6.1)	2.7 (0.1–6.1)	0.739 ^a	0.302 ^c	0.626 ^c	0.698 ^c
AVQI median (range)	4.5 (3.3–5.3)	4.5 (3.4–5.5)	4.5 (3.6–5.5)	0.901 ^a	0.905 ^c	0.723 ^c	0.473 ^c

NB Not all percentages sum up exactly to 100% due to rounding

AVQI acoustic voice quality index, FOIS functional oral intake scale, NGT nasogastric tube, PRG percutaneous radiological gastrostomy, SHI speech handicap index, *t*0 pretreatment, *t*1 6 months after treatment, *t*2 12 months after treatment

^a*P* values shown for Friedman test

^bCochran's Q test

^cWilcoxon signed rank test

^dMcNemar test

↑Indicating more problems

↓Indicating less problems

at six-month follow-up and stayed stable up until twelve-month follow-up. Subjective speech outcomes, however, deteriorated up until 6 months and returned to baseline levels at twelve-month follow-up. This is most likely because patients get used to the altered speech. Vainshtein et al. found the same trend in patient-reported voice quality, which decreased maximally at 1 month after treatment and recovered to baseline after 12 to 18 months [42]. In an earlier study from our institute, Jacobi et al. found comparable results. They reported that computer analyzed articulation and sound quality was impaired in head and neck cancer patients after RT +, especially with oral and oropharyngeal cancer sites [43].

The policy evaluated in this study was comparable to that applied in the control arm of the randomized trial by van der Molen et al. [22]. The proportion of patients with functional limitations at one-year follow-up of that study are substantially lower than observed in the current cohort [44]. Only 7% of the 49 included patients had a modified

diet (FOIS < 7) at one-year follow-up, compared to 25% of the patients in our study. Also, only 3% had trismus, compared to 20% in our study. The first explanation obviously is the heterogeneity of the patient cohorts. In our study, only OPC patients treated with radiotherapy-based treatment were included, while only 37% of the patients included in the randomized study had OPC, and all received chemoradiotherapy. Another, more important explanation is that in the setting of a randomized study, adherence to the rehabilitation protocol is likely to be higher, which might have resulted in better functional outcomes, supporting the benefit of the rehabilitation protocol, but also highlighting the challenges of achieving similar outcomes in regular practice.

Our results suggest that patients treated with concomitant systemic therapy have more functional limitations than patients treated with RT alone, although numbers were small. This might be due to the toxicity of systemic therapy, but might also be because of the higher tumor stages, and therefore also larger radiotherapy fields. Only 17 (16%) of the 108 included patients

were treated with cetuximab based RT+ and therefore there is a high risk of atypical sampling and conclusions on functional outcomes relative to RT only or cisplatin-based RT+ based on these analyses should be made with caution. A recently published randomized study concluded that the degree of toxicities, including dysphagia, between cisplatin and cetuximab in HPV positive OPC was comparable [5].

In our cohort, although HPV status was not associated with trismus and speech outcomes, patients with HPV positive tumors had less objective and subjective functional impairment. However, patients with HPV positive tumors also had more favorable baseline characteristics, including higher pretreatment SMI (as also reported by Chargi et al. [45]), lower T classification, were more often treated with RT only and less often had a modified diet before treatment. When adjusting for baseline characteristics in multivariable analyses, HPV status was not significantly associated with functional limitations, except for a smaller mouth opening at one-year post-treatment. Although no definite conclusions can be drawn, it seems that HPV status itself does not influence post-treatment functional limitations.

Results in literature have contrasting results regarding the association of HPV status with functional limitations after RT(+). Vangelov et al. evaluated 100 patients with OPC treated with RT(+), and found that after adjusting for baseline characteristics (i.e. smoking, nodal stage, IMRT, and oropharyngeal RT dose), patients with an HPV positive tumor more often had tube feeding and weight loss, compared to patients with an HPV negative tumor [46]. Again, adjusted for baseline characteristics (i.e. age, gender, stage, treatment modality, RT dose, neck node irradiation, and pretreatment weight loss), Vatca et al., on the other hand, evaluated 72 OPC patients treated with RT+ and found that patients with an HPV positive tumor had more mucositis and weight loss during treatment [47]. Sharma et al. evaluated 228 OPC patients and found that quality of life in HPV positive patients was lower shortly after treatment but became comparable by 1 year after treatment, also adjusted for baseline differences [48], which is similar to our findings.

A low skeletal muscle mass, or sarcopenia, before treatment, was associated with an impaired diet before and after treatment. This is in line with results of a previous study performed at our institute which demonstrated that sarcopenia is a strong determinant for feeding tube use after RT+ for head and neck cancer [20]. Skeletal muscle loss is thought to be related to swallowing muscle loss, causing swallowing difficulties which might result in a modified diet or eventually tube dependency. Moreover, swallowing problems itself may result in skeletal muscle loss due to insufficient nutritional

intake. Therefore, these results support the hypothesis that sarcopenia might be a relevant target to optimize patients' condition before as well as after treatment to improve functional status. Apparently, our current preventive rehabilitation protocol does not target muscle mass sufficiently and/or not sufficiently long enough to close the gap between sarcopenic and non-sarcopenic patients with regard to swallowing impairment. In view of the association between pretreatment sarcopenia and functional outcomes, integrating SMI determination before treatment is warranted.

Limitations

A limitation of this study is the suboptimal accrual during the first years of the data collection. These analyses were performed on data collected as part of standard care. Collecting data in this way usually introduced a risk for suboptimal inclusion especially during startup. Although at first inclusion rates were low, they improved over time with current inclusion rates between 79 and 85%, making it likely that this cohort is representative for the entire cohort. In addition, because baseline characteristics between included patients and not included patients were similar, no selection bias due to (non-)inclusion seems present. Another limitation of this study is that no data on adherence to the preventive rehabilitation protocol was collected, as this is not routinely registered in usual care. However, the observed outcomes thus realistically reflect the outcomes as they occur in clinical practice.

Conclusion

Objective and patient-perceived swallowing, mouth opening, and speech function of patients treated with IMRT with or without systemic therapy combined with a preventive rehabilitation program for OPC deteriorate up until 6 months and improve until 12 months after treatment, but do not return to baseline levels. Patients treated with cisplatin-based CRT, HPV negative tumors and patients with pretreatment sarcopenia were more likely to have functional limitations. HPV negative status itself is not likely to be a cause of functional limitations, but the associated unfavorable patient and tumor characteristics are. Pretreatment sarcopenia might be a relevant target for prehabilitation strategies. Although for most patients in this cohort organ preserving treatment resulted in function preservation, there is a proportion of patients with functional problems, suggesting room for improvement of the current rehabilitation program.

Appendix

See Table 5,6,7,8,9,10,11,12,13,14,15,16

Table 5 Functional outcomes at $t1$ and $t2$ stratified by inclusion year

	$t1$		$t2$	
	2013/2014 $n = 14$	2017/2018 $n = 40$	2013/2014 $n = 14$	2017/2018 $n = 29$
Swallowing outcomes				
Modified diet (FOIS < 7)				
No	9 (64)	26 (67)	13 (93)	20 (69)
Yes	5 (36)	13 (33)	1 (7)	9 (31)
Unknown	0	1	0	0
SWAL-QOL total score (0–100) median (range)	21 (0–37)	20 (0–77)	10 (0–26)	6 (0–37)
SWAL-QOL ≥ 14				
No	3 (43)	10 (42)	9 (75)	17 (77)
Yes	4 (57)	14 (58)	3 (25)	5 (23)
Unknown	7	16	2	7
Trismus outcomes				
Mouth opening in mm median (range)				
Trismus				
No	11 (85)	28 (76)	11 (79)	24 (83)
Yes	2 (15)	9 (24)	3 (21)	5 (17)
Unknown	1	3	0	1
Perceived trismus				
No	9 (82)	28 (78)	11 (85)	27 (93)
Yes	2 (18)	8 (22)	2 (15)	2 (7)
Unknown	3	4	1	0
Speech and voice outcomes				
Vowel space area (%) median (range)				
Vowel space area < 80%				
No	5 (50)	14 (39)	7 (58)	6 (24)
Yes	5 (50)	22 (61)	5 (42)	19 (76)
Unknown	4	4	2	4
SHI total score (0–120) median (range)	0 (0–7)	4 (0–60)	0 (0–22)	0 (0–40)
SHI ≥ 6				
No	6 (86)	9 (56)	9 (82)	12 (92)
Yes	1 (14)	71 (44)	2 (18)	1 (8)
Unknown	7	24	3	16

P values shown for multivariable regression adjusted for AJCC stage and modified diet at $t0$

NB Not all percentages sum up exactly to 100% due to rounding

FOIS functional oral intake scale, *HPV* human papillomavirus, *SHI* speech handicap index, $t1$ 6 months after treatment, $t2$ 12 months after treatment

Table 6 Baseline characteristics stratified by treatment modality

	Number of patients (%)			Total <i>n</i> = 108
	RT <i>n</i> = 42	RT + cetuximab <i>n</i> = 17	RT + cisplatin <i>n</i> = 49	
Gender				
Male	29 (69)	14 (82)	30 (61)	73 (68)
Female	13 (31)	3 (18)	19 (39)	35 (32)
Age at baseline median (range)	61 (39–81)	64 (56–79)	62 (42–72)	63 (39–81)
ACE-27				
0	19 (45)	4 (24)	30 (61)	53 (49)
1	14 (33)	7 (41)	16 (33)	37 (34)
2	7 (17)	5 (29)	2 (4)	14 (13)
3	2 (5)	1 (6)	1 (2)	4 (4)
BMI median (range)	26 (17–44)	25 (18–33)	24 (17–32)	25 (17–44)
SMM median (range)	45 (22–64)	45 (28–54)	42 (27–54)	44 (22–64)
Sarcopenia				
No	27 (64)	9 (53)	23 (47)	59 (55)
Yes	15 (36)	8 (47)	26 (53)	49 (45)
Oropharyngeal tumor site				
Base of tongue	16 (38)	3 (18)	16 (33)	35 (32)
Tonsil	21 (50)	12 (71)	24 (49)	57 (53)
Other	5 (12)	2 (12)	9 (18)	16 (15)
T classification				
T1	19 (45)	1 (6)	7 (14)	27 (25)
T2	19 (45)	6 (35)	5 (10)	30 (28)
T3	3 (7)	5 (29)	21 (43)	29 (27)
T4	1 (2)	5 (29)	16 (33)	22 (20)
N classification				
N0	1 (2)	5 (29)	6 (12)	12 (11)
N1	13 (31)	2 (12)	9 (18)	24 (22)
N2	27 (64)	10 (59)	32 (65)	69 (64)
N3	1 (2)	0 (0)	2 (4)	3 (3)
AJCC stage				
III	14 (33)	5 (29)	9 (18)	28 (26)
IV	28 (68)	12 (71)	40 (82)	80 (74)
HPV status				
Negative	7 (18)	8 (53)	18 (38)	33 (32)
Positive	33 (83)	7 (47)	30 (62)	70 (68)
Unknown	2	2	1	5
Treatment modality				
RT	39 (93)	0 (0)	0 (0)	39 (36)
RT unfit for RT +	3 (7)	0 (0)	0 (0)	3 (3)
RT + cetuximab	0 (0)	17 (100)	0 (0)	17 (16)
RT + cisplatin	0 (0)	0 (0)	49 (100)	49 (45)
Modified diet at #0 (FOIS < 7)				
No	36 (86)	16 (94)	37 (76)	89 (82)
Yes	6 (14)	1 (6)	12 (24)	19 (18)
Trismus at #0				
No	39 (93)	16 (94)	43 (96)	98 (94)
Yes	3 (7)	1 (6)	2 (4)	6 (6)
Unknown	0	0	4	4

NB Not all percentages sum up exactly to 100% due to rounding

BMI body mass index, *FOIS* functional oral intake scale, *HPV* human papilloma virus, *other* soft palate, uvula, oropharyngeal wall, vallecula or pharyngeal arch, *RT* radiotherapy, *SMM* skeletal muscle mass

Table 7 Swallowing outcomes at t_0 , t_1 and t_2 stratified by treatment modality

	RT			RT + cetuximab			RT + cisplatin		
	t_0 <i>n</i> = 42	t_1 <i>n</i> = 39	t_2 <i>n</i> = 28	t_0 <i>n</i> = 17	t_1 <i>n</i> = 17	t_2 <i>n</i> = 11	t_0 <i>n</i> = 49	t_1 <i>n</i> = 43	t_2 <i>n</i> = 32
Observer-rated outcome									
FOIS									
7	36 (86)	25 (64)	23 (82)	16 (94)	14 (82)	7 (64)	37 (76)	26 (62)	23 (72)
6	2 (5)	12 (31)	5 (18)	1 (6)	1 (6)	3 (27)	6 (12)	11 (26)	6 (19)
5	2 (5)	2 (5)	0 (0)	0 (0)	1 (6)	1 (9)	5 (10)	1 (2)	2 (6)
4	1 (2)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	1 (2)	1 (2)	1 (3)
3	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (7)	0 (0)
2	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
1	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Unknown	0	0	0	0	0	0	0	0	0
FOIS < 7									
No	36 (86)	25 (64)	23 (82)	16 (94)	14 (82)	7 (64)	37 (76)	26 (62)	23 (72)
Yes	6 (14)	14 (36)	5 (18)	1 (6)	3 (18)	4 (36)	12 (25)	16 (38)	9 (28)
Unknown	0	0	0	0	0	0	0	1	0
Patient-rated outcome									
SWAL-QOL (0–100) median (range)									
General burden	0 (0–88)	0 (0–50)	0 (0–38)	0 (0–50)	0 (0–100)	25 (0–50)	0 (0–75)	13 (0–63)	0 (0–50)
Food selection	0 (0–88)	0 (0–50)	0 (0–38)	0 (0–25)	25 (0–100)	25 (0–50)	7 (0–75)	19 (0–75)	0 (0–50)
Eating duration	0 (0–88)	32 (0–100)	13 (0–100)	0 (0–63)	38 (0–88)	38 (0–88)	19 (0–75)	50 (0–100)	38 (0–75)
Eating desire	0 (0–92)	17 (0–42)	8 (0–38)	9 (0–50)	25 (0–50)	34 (0–58)	13 (0–83)	25 (0–83)	17 (0–67)
Fear	0 (0–69)	0 (0–38)	0 (0–38)	0 (0–38)	25 (0–69)	16 (0–25)	0 (0–50)	19 (0–69)	16 (0–38)
Sleep	38 (0–100)	38 (0–75)	25 (0–88)	38 (0–88)	50 (0–75)	13 (0–63)	44 (0–88)	38 (0–75)	25 (0–50)
Fatigue	25 (0–67)	25 (0–58)	17 (0–83)	17 (0–50)	25 (0–75)	21 (0–50)	21 (0–67)	42 (0–75)	25 (0–83)
Communication	0 (0–50)	0 (0–38)	0 (0–25)	0 (0–50)	25 (0–75)	7 (0–25)	0 (0–75)	0 (0–63)	0 (0–63)
Mental health	0 (0–69)	0 (0–25)	0 (0–30)	0 (0–25)	25 (0–100)	20 (0–25)	0 (0–75)	3 (0–60)	0 (0–45)
Social functioning	0 (0–40)	0 (0–40)	0 (0–30)	0 (0–25)	25 (0–60)	0 (0–25)	0 (0–70)	0 (0–50)	0 (0–30)
Symptoms	11 (0–79)	15 (0–36)	13 (0–27)	5 (0–21)	14 (5–52)	15 (0–23)	7 (0–48)	20 (0–48)	14 (0–41)
Total score	1 (0–67)	6 (0–41)	2 (0–31)	3 (0–28)	21 (0–77)	25 (0–32)	10 (0–69)	18 (0–57)	10 (0–43)
SWAL-QOL \geq 14									
No	19 (68)	15 (68)	21 (91)	12 (86)	5 (39)	3 (38)	21 (58)	15 (47)	14 (64)
Yes	9 (32)	7 (32)	2 (9)	2 (14)	8 (62)	5 (63)	15 (42)	17 (53)	8 (36)
Unknown	14	17	5	3	4	3	12	11	10
Secondary outcomes									
Feeding tube									
No	41 (98)	39 (100)	28 (100)	17 (100)	15 (88)	11 (100)	48 (98)	39 (91)	32 (100)
Yes NGT	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Yes PRG	0 (0)	0 (0)	0 (0)	0 (0)	2 (12)	0 (0)	1 (2)	4 (9)	0 (0)
Unknown	0	0	0	0	0	0	0	0	0
Pneumonia									
No	40 (95)	34 (97)	27 (96)	16 (94)	16 (94)	10 (91)	42 (98)	40 (98)	30 (97)
Yes	2 (5)	1 (3)	1 (4)	1 (6)	1 (6)	1 (9)	1 (2)	1 (2)	1 (3)
Unknown	0	4	0	0	0	0	6	2	1

NB Not all percentages sum up exactly to 100% due to rounding

FOIS functional oral intake scale, t_0 pretreatment, t_1 6 months after treatment, t_2 12 months after treatment

^a*P* values shown for Friedman test

^bCochran's Q test

Table 8 Trismus outcomes at *t*0, *t*1 and *t*2 stratified by treatment modality

	RT			RT + cetuximab			RT + cisplatin		
	<i>t</i> 0 <i>n</i> = 42	<i>t</i> 1 <i>n</i> = 39	<i>t</i> 2 <i>n</i> = 28	<i>t</i> 0 <i>n</i> = 17	<i>t</i> 1 <i>n</i> = 17	<i>t</i> 2 <i>n</i> = 11	<i>t</i> 0 <i>n</i> = 49	<i>t</i> 1 <i>n</i> = 43	<i>t</i> 2 <i>n</i> = 32
Observer-rated outcomes									
Mouth opening in mm median (range)	49 (25–65)	47 (31–63)	48 (27–64)	48 (30–60)	42 (27–55)	43 (32–50)	47 (18–64)	40 (16–59)	41 (10–58)
Trismus									
No	39 (93)	29 (91)	24 (86)	16 (94)	12 (75)	9 (90)	43 (96)	27 (68)	22 (71)
Yes	3 (7)	3 (9)	4 (14)	1 (6)	4 (25)	1 (10)	2 (4)	13 (33)	9 (29)
Unknown	0	7	0	0	1	1	4	3	1
Patient-rated outcomes									
Perceived trismus									
No	34 (100)	26 (90)	25 (93)	16 (94)	13 (81)	8 (100)	37 (93)	28 (76)	23 (82)
Yes	0 (0)	3 (10)	2 (7)	1 (6)	3 (19)	0 (0)	3 (8)	9 (24)	5 (18)
Unknown	8	10	1	0	1	3	9	6	4

NB Not all percentages sum up exactly to 100% due to rounding

FOIS functional oral intake scale, *NGT* nasogastric tube, *PRG* percutaneous radiological gastrostomy, *t*0 pretreatment, *t*1 6 months after treatment, *t*2 12 months after treatment

Table 9 Speech outcomes at *t*0, *t*1 and *t*2 stratified by treatment modality

	RT			RT + cetuximab			RT + cisplatin		
	<i>t</i> 0 <i>n</i> = 42	<i>t</i> 1 <i>n</i> = 39	<i>t</i> 2 <i>n</i> = 28	<i>t</i> 0 <i>n</i> = 17	<i>t</i> 1 <i>n</i> = 17	<i>t</i> 2 <i>n</i> = 11	<i>t</i> 0 <i>n</i> = 49	<i>t</i> 1 <i>n</i> = 43	<i>t</i> 2 <i>n</i> = 32
Observer-rated outcomes									
Vowel space area (%) median (range)	92 (61–128)	86 (56–107)	83 (53–112)	86 (68–129)	74 (59–97)	69 (53–96)	81 (51–114)	76 (49–102)	76 (51–97)
Vowel space area < 80%									
No	25 (76)	20 (69)	13 (59)	10 (63)	6 (38)	2 (22)	24 (53)	11 (36)	9 (35)
Yes	8 (24)	9 (31)	9 (41)	6 (38)	10 (63)	7 (78)	21 (47)	20 (65)	17 (65)
Unknown	9	10	6	1	1	2	4	12	6
Patient-rated outcomes									
SHI median (range)									
Speech domain (0–56)	1 (0–18)	2 (0–21)	0 (0–14)	0 (0–25)	2 (0–27)	0 (0–6)	0 (0–42)	2 (0–32)	1 (0–31)
Psychosocial domain (0–56)	0 (0–5)	0 (0–10)	0 (0–7)	0 (0–32)	0 (0–34)	0 (0–1)	0 (0–39)	0 (0–19)	0 (0–15)
Total score (0–120)	1 (0–23)	2 (0–36)	0 (0–23)	0 (0–57)	2 (0–61)	0 (0–6)	0 (0–83)	3 (0–52)	1 (0–40)
SHI ≥ 6									
No	23 (82)	13 (65)	16 (94)	12 (86)	10 (77)	6 (86)	30 (83)	16 (62)	14 (82)
Yes	5 (18)	7 (35)	1 (6)	2 (14)	3 (23)	1 (14)	6 (17)	10 (39)	3 (18)
Unknown	14	19	11	3	4	4	13	17	15
Secondary outcomes									
Articulation rate (syllables/s) median (range)	2.2 (0.9–7.7)	2.8 (1.4–4.2)	2.9 (0.1–5.0)	2.7 (1.0–4.3)	2.6 (0.6–4.6)	2.7 (1.6–5.1)	2.2 (0.2–5.8)	2.6 (0.6–6.1)	2.4 (0.6–6.1)
AVQI median (range)	4.7 (3.7–5.3)	4.5 (3.4–5.5)	4.7 (4.1–5.3)	4.4 (3.7–5.1)	4.4 (3.6–5.1)	4.5 (4.1–5.2)	4.5 (3.3–5.2)	4.5 (3.5–5.3)	4.5 (3.6–5.5)

NB Not all percentages sum up exactly to 100% due to rounding

AVQI acoustic voice quality index, *FOIS* functional oral intake scale, *SHI* speech handicap index, *t*0 pretreatment, *t*1 6 months after treatment, *t*2 12 months after treatment

Table 10 Baseline characteristics by modified diet (FOIS < 7) at *t*2 and univariable analysis

	Normal diet (FOIS 7) at <i>t</i> 1 <i>n</i> = 53	Modified diet (FOIS < 7) at <i>t</i> 1 <i>n</i> = 18	Univariable logistic regression analysis	
			OR (95% CI)	<i>P</i> value
Gender				
Male	40 (76)	12 (67)	1.0	
Female	13 (25)	6 (33)	1.5 (0.5–4.9)	0.468
Age at baseline median (range)	62 (39–81)	63 (47–75)	1.0 (1.0–1.1)	0.477
ACE-27				0.963
0	28 (53)	11 (61)	1.0	
1	20 (38)	6 (33)	0.8 (0.2–2.4)	0.645
2	2 (4)	1 (6)	1.3 (0.1–15.5)	0.850
3	3 (6)	0 (0)	NA	NA
BMI median (range)	25 (17–44)	23 (18–30)	0.8 (0.7–1.0)	0.020
SMM median (range)	45 (27–64)	41 (30–54)	0.9 (0.8–1.0)	0.034
Sarcopenia				
No	36 (68)	8 (44)	1.0	
Yes	17 (32)	10 (56)	2.6 (0.9–7.9)	0.081
Tumor site				0.588
Base of tongue	20 (38)	5 (28)	1.0	
Tonsil	26 (49)	9 (50)	1.4 (0.4–4.8)	0.607
Other	7 (13)	4 (22)	2.3 (0.5–11.0)	0.303
T classification				0.222
T1	18 (34)	1 (6)	1.0	
T2	13 (25)	6 (33)	8.3 (0.9–77.6)	0.063
T3	14 (26)	6 (33)	7.7 (0.8–71.7)	0.072
T4	8 (15)	5 (28)	11.3 (1.1–112.5)	0.039
HPV status				
Negative	13 (25)	5 (29)	1.0	
Positive	39 (75)	12 (71)	0.8 (0.2–2.7)	0.719
Unknown	1	1		
Treatment modality				0.444
RT	23 (43)	5 (28)	1.0	
RT + cetuximab	7 (13)	4 (22)	2.6 (0.6–12.6)	0.226
RT + cisplatin	23 (43)	9 (50)	1.8 (0.5–6.2)	0.352
Pretreatment modified diet (FOIS < 7)				
No	50 (94)	16 (89)	1.0	
Yes	3 (6)	2 (11)	2.1 (0.3–13.6)	0.443

NB Not all percentages sum up exactly to 100% due to rounding

BMI body mass index, *CI* confidence interval, *HPV* human papilloma virus, *FOIS* functional oral intake scale, *OR* odds ratio, other soft palate, uvula, oropharyngeal wall, vallecula or pharyngeal arch, *RT* radiotherapy, *sarcopenia* SMM below 43.2 cm²/m², *SMM* skeletal muscle mass

Table 11 Baseline characteristics by trismus at *t2* and univariable analysis

	No trismus at <i>t1</i> <i>n</i> = 55	Trismus at <i>t1</i> <i>n</i> = 14	Univariable logistic regression analysis	
			OR (95% CI)	<i>P</i> value
Gender				
Male	39 (71)	12 (86)	1.0	
Female	16 (29)	2 (14)	0.4 (0.1–2.0)	0.272
Age at baseline median (range)	60 (39–77)	64 (42–73)	1.1 (1.0–1.1)	0.154
ACE-27				0.886
0	31 (56)	7 (50)	1.0	
1	19 (35)	7 (50)	1.6 (0.5–5.4)	0.421
2	2 (4)	0 (0)	NA	NA
3	3 (6)	0 (0)	NA	NA
BMI median (range)	26 (17–44)	24 (18–30)	0.9 (0.7–1.0)	0.073
SMM median (range)	45 (22–64)	44 (34–50)	1.0 (0.9–1.1)	0.617
Sarcopenia				
No	35 (64)	8 (57)	1.0	
Yes	20 (36)	6 (43)	1.3 (0.4–4.3)	0.655
Tumor site				0.142
Base of tongue	23 (42)	2 (14)	1.0	
Tonsil	25 (46)	8 (57)	3.7 (0.7–19.2)	0.122
Other	7 (13)	4 (29)	6.6 (1.0–43.8)	0.052
T classification				0.164
T1	17 (31)	2 (14)	1.0	
T2	17 (31)	2 (14)	1.0 (0.1–7.9)	1.000
T3	12 (22)	7 (50)	5.0 (0.9–28.2)	0.071
T4	9 (16)	3 (21)	2.8 (0.4–1.2)	0.298
HPV status				
Negative	15 (28)	2 (14)	1.0	
Positive	38 (72)	12 (86)	2.4 (0.5–11.9)	0.294
Unknown	2	0		
Treatment modality				0.272
RT	24 (44)	4 (29)	1.0	
RT + cetuximab	9 (16)	1 (7)	0.7 (0.1–6.8)	0.732
RT + cisplatin	22 (40)	9 (64)	2.5 (0.7–9.1)	0.180
Pretreatment trismus				
No	52 (96)	10 (83)		
Yes	2 (4)	2 (17)	5.2 (0.7–41.4)	0.119
Unknown	1	2		

NB Not all percentages sum up exactly to 100% due to rounding

BMI body mass index, *CI* confidence interval, *HPV* human papilloma virus, *FOIS* functional oral intake scale, *OR* odds ratio, *other* soft palate, uvula, oropharyngeal wall, vallecula or pharyngeal arch, *RT* radiotherapy, *sarcopenia SMM* below 43.2 cm²/m², *SMM* skeletal muscle mass

Table 12 Baseline characteristics by vowel space area below 80% at *t1* and univariable analysis

	VSA > 80% at <i>t1</i> <i>n</i> = 24	VSA < 80% <i>t1</i> <i>n</i> = 33	Univariable logistic regression analysis	
			OR (95% CI)	<i>P</i> value
Gender				
Male	20 (83)	24 (73)	1.0	
Female	4 (17)	9 (27)	1.9 (0.5–7.0)	0.350
Age at baseline median (range)	61 (44–75)	60 (39–75)	1.0 (1.0–1.1)	0.756
ACE-27				0.501
0	12 (50)	21 (64)	1.0	
1	11 (46)	8 (24)	0.4 (0.1–1.3)	0.136
2	0 (0)	2 (6)	NA	
3	1 (4)	2 (6)	1.1 (0.1–14.0)	0.917
BMI median (range)	26 (20–44)	25 (18–33)	1.0 (0.8–1.1)	0.473
SMM median (range)	46 (32–64)	45 (30–54)	1.0 (0.9–1.0)	0.345
Sarcopenia				
No	18 (75)	20 (61)	1.0	
Yes	6 (25)	13 (39)	2.0 (0.6–6.2)	0.258
Tumor site				0.756
Base of tongue	8 (33)	14 (42)	1.0	
Tonsil	12 (50)	15 (46)	0.7 (0.2–2.3)	0.568
Other	4 (17)	4 (12)	0.6 (0.1–2.9)	0.502
T classification				0.963
T1	7 (29)	8 (24)	1.0	
T2	7 (29)	10 (30)	1.3 (0.3–5.1)	0.755
T3	6 (25)	8 (24)	1.2 (0.3–5.1)	0.837
T4	4 (17)	7 (21)	1.5 (0.3–7.5)	0.600
HPV status				
Negative	7 (30)	9 (28)	1.0	
Positive	16 (70)	23 (72)	1.1 (0.3–3.6)	0.852
Unknown	1	1		
Treatment modality				0.108
RT	13 (54)	9 (27)	1.0	
RT + cetuximab	2 (8)	7 (21)	5.1 (0.8–30.2)	0.075
RT + cisplatin	9 (38)	17 (52)	2.7 (0.8–8.8)	0.093
Pretreatment VSA < 80%				
No	17 (77)	14 (48)	1.0	
Yes	4 (24)	15 (52)	4.6 (1.2–16.9)	0.023
Unknown	3	4		

NB Not all percentages sum up exactly to 100% due to rounding

BMI body mass index, *CI* confidence interval, *HPV* human papilloma virus, *FOIS* functional oral intake scale, *OR* odds ratio, *other* soft palate, uvula, oropharyngeal wall, vallecula or pharyngeal arch, *RT* radiotherapy, *sarcopenia* *SMM* below 43.2 cm²/m², *SMM* skeletal muscle mass, *VSA* vowel space area

Table 13 Baseline characteristics stratified by HPV status

	HPV – n = 33	HPV + n = 70	P value
Gender			
Male	20 (61)	50 (71)	0.366 ^c
Female	13 (39)	20 (29)	
Age at baseline median (range)	62 (44–75)	62 (39–79)	0.511 ^a
ACE-27			
0	14 (42)	38 (54)	0.151 ^b
1	13 (39)	24 (34)	
2	3 (9)	7 (10)	
3	3 (9)	1 (1)	
BMI median (range)	24 (17–33)	26 (17–44)	0.001 ^a
SMM median (range)	41 (27–54)	45 (22–64)	0.031 ^a
Sarcopenia			
No	14 (42)	43 (61)	0.090 ^c
Yes	19 (58)	27 (39)	
Oropharyngeal tumor site			
Base of tongue	10 (30)	24 (34)	0.198 ^b
Tonsil	15 (46)	40 (57)	
Other	8 (24)	6 (9)	
T classification			
T1	1 (3)	26 (37)	<0.001 ^b
T2	7 (21)	21 (30)	
T3	15 (46)	11 (16)	
T4	10 (30)	12 (17)	
N classification			
N0	6 (18)	5 (7)	0.026 ^b
N1	9 (27)	13 (19)	
N2	18 (55)	49 (70)	
N3	0 (0)	3 (4)	
AJCC stage			
III	10 (30)	15 (21)	0.336 ^c
IV	23 (70)	55 (79)	
Treatment modality			
RT	6 (18)	32 (46)	0.005 ^b
RT unfit for RT +	1 (3)	1 (1)	
RT + cetuximab	18 (55)	30 (43)	
RT + cisplatin	8 (24)	7 (10)	
Modified diet at t0 (FOIS < 7)			
No	20 (61)	64 (91)	0.001 ^c
Yes	13 (39)	6 (9)	
Trismus at t0			
No	28 (90)	66 (97)	0.175 ^c
Yes	3 (10)	2 (3)	
Unknown	2	2	

NB: Not all percentages sum up exactly to 100% due to rounding

BMI body mass index, *HPV* human papilloma virus, other soft palate, uvula, oropharyngeal wall, vallecule or pharyngeal arch, *RT* radiotherapy, *sarcopenia SMM* below 43.2 cm²/m², *SMM* skeletal muscle mass

^a*P* values shown for Mann–Whitney *U* test

^bLinear-by-linear approximation of the Pearson's Chi-square test

^cFisher's exact test

Table 14 Functional outcomes at *t*1 and *t*2 stratified by HPV status.

	<i>t</i> 1			<i>t</i> 2		
	HPV – <i>n</i> = 31	HPV + <i>n</i> = 64	Adjusted <i>p</i> value	HPV – <i>n</i> = 18	HPV + <i>n</i> = 51	Adjusted <i>p</i> value
Swallowing outcomes						
Modified diet (FOIS < 7)						
No	19 (61)	43 (68)	0.206	13 (72)	39 (77)	0.460
Yes	12 (39)	20 (32)		5 (28)	12 (24)	
Unknown	0	1		0	0	
SWAL-QOL total score (0–100) median (range)	21 (0–77)	8 (0–52)	0.492	14 (0–32)	5 (0–43)	0.652
SWAL-QOL ≥ 14						
No	9 (38)	26 (65)	0.868	8 (62)	29 (76)	0.292
Yes	15 (63)	14 (35)		5 (39)	9 (24)	
Unknown	7	24		5	13	
Trismus outcomes						
Mouth opening in mm median (range)	42 (18–54)	45 (16–63)	0.627	45 (27–53)	43 (10–64)	0.046
Trismus						
No	23 (77)	43 (78)	0.611	15 (88)	38 (76)	0.086
Yes	7 (23)	12 (22)		2 (12)	12 (24)	
Unknown	1	9		1	1	
Perceived trismus						
No	25 (86)	40 (80)	0.074	15 (94)	39 (87)	0.996
Yes	4 (14)	10 (20)		1 (6)	6 (13)	
Unknown	2	14		2	6	
Speech and voice outcomes						
Vowel space area (%) median (range)	77 (58–100)	82 (49–107)	0.913	77 (51–102)	76 (53–112)	0.528
Vowel space area < 80%						
No	13 (48)	43 (78)	0.645	7 (44)	16 (41)	0.463
Yes	14 (52)	12 (22)		9 (56)	23 (59)	
Unknown	4	9		2	12	
SHI total score (0–120) median (range)	4 (0–61)	3 (0–52)	0.896	1 (0–10)	0 (0–40)	0.151
SHI ≥ 6						
No	12 (60)	25 (69)	0.995	11 (85)	24 (92)	0.325
Yes	8 (40)	11 (31)		2 (15)	2 (8)	
Unknown	11	28		5	25	

P values shown for multivariable regression adjusted for T and N classification, treatment and modified diet at *t*0

NB Not all percentages sum up exactly to 100% due to rounding

FOIS functional oral intake scale, *HPV* human papillomavirus, *SHI* speech handicap index, *t*1 6 months after treatment, *t*2 12 months after treatment

Table 15 Baseline characteristics stratified by pretreatment sarcopenia

	No sarcopenia N=59	Sarcopenia N=49	P value
Gender			
Male	57 (97)	16 (33)	<0.001 ^c
Female	2 (3)	33 (67)	
Age at baseline median (range)	61 (39–81)	63 (47–79)	0.095 ^a
ACE-27			
0	29 (49)	24 (49)	1.000 ^b
1	21 (36)	16 (33)	
2	6 (10)	8 (16)	
3	3 (5)	1 (2)	
BMI median (range)	26 (18–44)	23 (17–35)	<0.001 ^a
Oropharyngeal tumor site			
Base of tongue	22 (37)	13 (27)	0.112 ^b
Tonsil	31 (53)	26 (53)	
Other	6 (10)	10 (20)	
T classification			
T1	19 (32)	8 (16)	0.031 ^b
T2	16 (27)	14 (29)	
T3	16 (27)	13 (27)	
T4	8 (14)	14 (29)	
N classification			
N0	8 (14)	4 (8)	0.287 ^b
N1	15 (25)	9 (18)	
N2	34 (58)	35 (71)	
N3	2 (3)	1 (2)	
AJCC stage			
III	20 (34)	8 (16)	0.048 ^c
IV	39 (66)	41 (84)	
HPV			
Negative	14 (25)	19 (41)	0.090 ^c
Positive	43 (75)	27 (59)	
Unknown	2	3	
Treatment modality			
RT	27 (46)	12 (24)	0.090 ^b
RT unfit for RT +	0 (0)	3 (6)	
RT + cetuximab	9 (15)	8 (16)	
RT + cisplatin	23 (39)	26 (53)	
Modified diet at t0 (FOIS < 7)			
No	53 (90)	36 (74)	0.041 ^c
Yes	6 (10)	13 (27)	
Trismus at t0			
No	54 (96)	44 (92)	0.411 ^c
Yes	2 (4)	4 (8)	
Unknown	3	1	

NB Not all percentages sum up exactly to 100% due to rounding

BMI body mass index, *HPV* human papilloma virus, other soft palate, uvula, oropharyngeal wall, vallecula or pharyngeal arch, *RT* radiotherapy, *sarcopenia* skeletal muscle mass below 43.2 cm²/m²

^a*P* values shown for Mann–Whitney *U* test

^bLinear-by-linear approximation of the Pearson's Chi-square test

^cFisher's exact test

Table 16 Functional outcomes at *t*1 and *t*2 stratified by pretreatment sarcopenia

	<i>t</i> 1			<i>t</i> 2		
	No sarcopenia <i>n</i> = 53	Sarcopenia <i>n</i> = 46	Adjusted <i>p</i> value	No sarcopenia <i>n</i> = 44	Sarcopenia <i>n</i> = 27	Adjusted <i>p</i> value
Swallowing outcomes						
Modified diet (FOIS < 7)						
No	41 (79)	24 (52)	0.013	36 (82)	17 (63)	0.088
Yes	11 (21)	22 (48)		8 (18)	10 (37)	
Unknown	1	0		0	0	
SWAL-QOL total score (0–100) median (range)	10 (0–41)	22 (0–77)	0.031	9 (0–32)	8 (0–43)	0.133
SWAL-QOL ≥ 14						
No	23 (64)	12 (39)	0.135	26 (70)	12 (75)	0.783
Yes	13 (36)	19 (61)		11 (30)	4 (25)	
Unknown	17	15		7	11	
Trismus outcomes						
Mouth opening in mm median (range)	45 (27–63)	44 (16–58)	0.528	45 (27–64)	43 (10–52)	0.143
Trismus						
No	37 (77)	31 (78)	0.662	35 (81)	20 (77)	0.831
Yes	11 (23)	9 (23)		8 (19)	6 (23)	
Unknown	5	6		1	1	
Perceived trismus						
No	37 (82)	30 (81)	0.958	35 (90)	21 (88)	0.892
Yes	8 (18)	7 (19)		4 (10)	3 (13)	
Unknown	8	9		5	3	
Speech and voice outcomes						
Vowel space area (%) median (range)	80 (56–107)	79 (49–100)	0.760	79 (51–112)	73 (53–102)	0.731
Vowel space area < 80%						
No	21 (49)	16 (49)	0.085	18 (47)	6 (32)	0.431
Yes	22 (51)	17 (52)		20 (53)	13 (68)	
Unknown	10	13		6	8	
SHI total score (0–120) median (range)	0 (0–36)	3 (0–61)	0.115	0 (0–23)	1 (0–40)	0.210
SHI ≥ 6						
No	24 (73)	15 (58)	0.266	25 (89)	11 (85)	0.563
Yes	9 (27)	11 (42)		3 (11)	2 (15)	
Unknown	20	20		16	14	

P values shown for multivariable regression adjusted for AJCC stage and modified diet at *t*0

NB Not all percentages sum up exactly to 100% due to rounding

FOIS functional oral intake scale, *HPV* human papillomavirus, *SHI* speech handicap index, sarcopenia skeletal muscle mass below 43.2 cm²/m², *t*1 6 months after treatment, *t*2 12 months after treatment

Acknowledgements We would like to acknowledge the speech-language pathologists at our institute Anne Kornman, Merel Latenstein, Klaske van Sluis, and Nadya van Gent for the data collection. Jasmine de Jong is acknowledged for her contribution to building the database. The Netherlands Cancer Institute receives a research grant from Atos Medical Sweden, which contributes to the existing infrastructure for health-related, quality-of-life research in the Department of Head and Neck Oncology and Surgery.

References

1. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S et al (2013) Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol* 31(36):4550–4559
2. Kreeft A, Tan IB, van den Brekel MW, Hilgers FJ, Balm AJ (2009) The surgical dilemma of 'functional inoperability' in oral and oropharyngeal cancer: current consensus on operability with regard to functional results. *Clin Otolaryngol* 34(2):140–146
3. Lazarus C, Logemann JA, Pauloski BR, Rademaker AW, Helenowski IB, Vonesh EF et al (2007) Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer. *Head Neck* 29(7):632–637
4. Hutcheson KA, Lewin JS, Barringer DA, Lisec A, Gunn GB, Moore MW et al (2012) Late dysphagia after radiotherapy-based treatment of head and neck cancer. *Cancer* 118(23):5793–5799
5. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. *Lancet (London, England)* 393(10166):51–60
6. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. *Lancet (London, England)* 393(10166):40–50
7. Wall LR, Ward EC, Cartmill B, Hill AJ (2013) Physiological changes to the swallowing mechanism following (chemo) radiotherapy for head and neck cancer: a systematic review. *Dysphagia* 28(4):481–493
8. Grant S, Kamal M, Mohamed ASR, Zaveri J, Barrow MP, Gunn GB et al (2019) Single-item discrimination of quality-of-life-altering dysphagia among 714 long-term oropharyngeal cancer survivors: comparison of patient-reported outcome measures of swallowing. *Cancer* 125(10):1654–1664
9. Starmer HM, Tippett D, Webster K, Quon H, Jones B, Hardy S et al (2014) Swallowing outcomes in patients with oropharyngeal cancer undergoing organ-preservation treatment. *Head Neck* 36(10):1392–1397
10. Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA et al (2013) Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. *Int J Radiat Oncol Biol Phys* 85(4):935–940
11. van der Molen L, Heemsbergen WD, de Jong R, van Rossum MA, Smeele LE, Rasch CR et al (2013) Dysphagia and trismus after concomitant chemo-intensity-modulated radiation therapy (chemo-IMRT) in advanced head and neck cancer; dose-effect relationships for swallowing and mastication structures. *Radiother Oncol* 106(3):364–369
12. Lindblom U, Garskog O, Kjellen E, Laurell G, Levring Jaghagen E, Wahlberg P et al (2014) Radiation-induced trismus in the ARTSCAN head and neck trial. *Acta Oncologica (Stockholm, Sweden)* 53(5):620–627
13. van der Geer SJ, Kamstra JI, Roodenburg JL, van Leeuwen M, Reintsema H, Langendijk JA et al (2016) Predictors for trismus in patients receiving radiotherapy. *Acta Oncologica (Stockholm, Sweden)* 55(11):1318–1323
14. van der Geer SJ, van Rijn PV, Kamstra JI, Langendijk JA, van der Laan B, Roodenburg JLN et al (2019) Prevalence and prediction of trismus in patients with head and neck cancer: a cross-sectional study. *Head Neck* 41(1):64–71
15. Watters AL, Cope S, Keller MN, Padilla M, Enciso R (2019) Prevalence of trismus in patients with head and neck cancer: a systematic review with meta-analysis. *Head Neck* 41(9):3408–3421
16. Kraaijenga SA, Hamming-Vrieze O, Verheijen S, Lamers E, van der Molen L, Hilgers FJ et al (2019) Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer. *Head Neck* 41(5):1387–1394
17. Van den Steen L, Van Gestel D, Vanderveken O, Vanderwegen J, Lazarus C, Daisne JF et al (2019) Evolution of self-perceived swallowing function, tongue strength and swallow-related quality of life during radiotherapy in head and neck cancer patients. *Head Neck* 41(7):2197–2207
18. Balm AJ, Rasch CR, Schornagel JH, Hilgers FJ, Keus RB, Schultze-Kool L et al (2004) High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. *Head Neck* 26(6):485–493
19. Ackerstaff AH, Balm AJ, Rasch CR, de Boer JP, Wiggenraad R, Rietveld DH et al (2009) First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial. *Head Neck* 31(1):77–84
20. Karsten RT, Al-Mamgani A, Bril SI, Tjon AJS, van der Molen L, de Boer JP et al (2019) Sarcopenia, a strong determinant for prolonged feeding tube dependency after chemoradiotherapy for head and neck cancer. *Head Neck* 41(11):4000–4008
21. Olson B, Edwards J, Stone L, Jiang A, Zhu X, Holland J et al (2020) Association of sarcopenia with oncologic outcomes of primary surgery or definitive radiotherapy among patients with localized oropharyngeal squamous cell carcinoma. *JAMA Otolaryngol Head Neck Surg*. <https://doi.org/10.1001/jamaoto.2020.1154>
22. van der Molen L, van Rossum MA, Burkhead LM, Smeele LE, Rasch CR, Hilgers FJ (2011) A randomized preventive rehabilitation trial in advanced head and neck cancer patients treated with chemoradiotherapy: feasibility, compliance, and short-term effects. *Dysphagia* 26(2):155–170
23. Retel VP, van der Molen L, Steuten LM, van den Brekel MW, Hilgers FJ (2016) A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. *Eur Arch Otorhinol*. 273(3):709–718
24. Passchier E, Stuiver MM, van der Molen L, Kerkhof SI, van den Brekel MW, Hilgers FJ (2016) Feasibility and impact of a dedicated multidisciplinary rehabilitation program on health-related quality of life in advanced head and neck cancer patients. *Eur Arch Otorhinol* 273(6):1577–1587
25. Swartz JE, Pothen AJ, Wegner I, Smid EJ, Swart KM, de Bree R et al (2016) Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. *Oral Oncol* 62:28–33
26. Wendrich AW, Swartz JE, Bril SI, Wegner I, de Graeff A, Smid EJ et al (2017) Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. *Oral Oncol* 71:26–33
27. Crary MA, Mann GD, Groher ME (2005) Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. *Arch Phys Med Rehabil* 86(8):1516–1520

28. McHorney CA, Robbins J, Lomax K, Rosenbek JC, Chignell K, Kramer AE et al (2002) The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III documentation of reliability and validity. *Dysphagia* 17(2):97–114
29. Rinkel RN, Verdonck-de Leeuw IM, Langendijk JA, van Reij EJ, Aaronson NK, Leemans CR (2009) The psychometric and clinical validity of the SWAL-QOL questionnaire in evaluating swallowing problems experienced by patients with oral and oropharyngeal cancer. *Oral Oncol* 45(8):e67-71
30. Lazarus CL, Husaini H, Hu K, Culliney B, Li Z, Urken M et al (2014) Functional outcomes and quality of life after chemoradiotherapy: baseline and 3 and 6 months post-treatment. *Dysphagia* 29(3):365–375
31. Boersma P (2001) Praat, a system for doing phonetics by computer. *Glott Int* 5(9/10):341–345
32. van Son RJ, Middag C, Demuynck K (2018) Vowel space as a tool to evaluate articulation problems. *Interspeech* 2018–68:357–361
33. Rinkel RN, Verdonck-de Leeuw IM, van Reij EJ, Aaronson NK, Leemans CR (2008) Speech handicap index in patients with oral and pharyngeal cancer: better understanding of patients' complaints. *Head Neck* 30(7):868–874
34. Dwivedi RC, St Rose S, Chisholm EJ, Bisase B, Amen F, Nutting CM et al (2012) Evaluation of speech outcomes using English version of the Speech Handicap Index in a cohort of head and neck cancer patients. *Oral Oncol* 48(6):547–553
35. de Jong NH, Wempe T (2009) Praat script to detect syllable nuclei and measure speech rate automatically. *Behav Res Methods* 41(2):385–390
36. Maryn Y, De Bodt M, Roy N (2010) The Acoustic Voice Quality Index: toward improved treatment outcomes assessment in voice disorders. *J Commun Disord* 43(3):161–174
37. van Sluis KE, van den Brekel MWM, Hilgers FJM, van Son RJH (2016) Long-term stability of tracheoesophageal voices. In: *Proceedings of interspeech 2016*, San Francisco, 102–6.
38. Morley L, Tsang SW, Breen SL, Waldron JN, Maganti M, Pintilie M et al (2014) Technical challenges of sparing infrahyoid swallowing organs at risk in oropharynx squamous cell cancer treated with IMRT. *Med Dosim* 39(2):146–151
39. Goepfert RP, Lewin JS, Barrow MP, Fuller CD, Lai SY, Song J et al (2017) Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. *Laryngoscope* 127(4):842–848
40. Astradsson T, Laurell G, Ahlberg A, Nikolaidis P, Johansson H, Ehrsson YT (2018) Trismus in patients with head and neck cancer and 5-year overall survival. *Acta Otolaryngol* 138(12):1123–1127
41. Karlsson O, Karlsson T, Pauli N, Andrell P, Finizia C (2020) Jaw exercise therapy for the treatment of trismus in head and neck cancer: a prospective three-year follow-up study. *Support Care Cancer*. <https://doi.org/10.1007/s00520-020-05517-7>
42. Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A (2014) Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. *Int J Radiat Oncol Biol Phys* 89(5):973–980
43. Jacobi I, van Rossum MA, van der Molen L, Hilgers FJ, van den Brekel MW (2013) Acoustic analysis of changes in articulation proficiency in patients with advanced head and neck cancer treated with chemoradiotherapy. *Ann Otol Rhinol Laryngol* 122(12):754–762
44. van der Molen L, van Rossum MA, Rasch CR, Smeele LE, Hilgers FJ (2014) Two-year results of a prospective preventive swallowing rehabilitation trial in patients treated with chemoradiation for advanced head and neck cancer. *Eu Arch otorhinol* 271(5):1257–1270
45. Charki N, Bril SI, Swartz JE, Wegner I, Willems SM, de Bree R (2020) Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma. *Oral oncol* 101:104519
46. Vangelov B, Kotevski DP, Williams JR, Smee RI (2018) The impact of HPV status on weight loss and feeding tube use in oropharyngeal carcinoma. *Oral Oncol* 79:33–39
47. Vatca M, Lucas JT Jr, Laudadio J, D'Agostino RB, Waltonen JD, Sullivan CA et al (2014) Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. *Oral Oncol* 50(9):869–876
48. Sharma A, Mendez E, Yueh B, Lohavanichbutr P, Houck J, Doody DR et al (2012) Human papillomavirus-positive oral cavity and oropharyngeal cancer patients do not have better quality-of-life trajectories. *Otolaryngol Head Neck Surg* 146(5):739–745

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.